Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
55 hedge funds and large institutions have $45M invested in Adverum Biotechnologies in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 9 closing their positions.
36% more capital invested
Capital invested by funds: $33.1M → $45M (+$11.9M)
0.54% more ownership
Funds ownership: 5.75% → 6.29% (+0.54%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 59 → 55 (-4)
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$3.54M |
| 2 |
Goldman Sachs
New York
|
+$3.22M |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$194K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$99.1K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$63.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGL
Sonic GP LLC
Honolulu,
Hawaii
|
-$1.8M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$269K |
| 3 |
BlackRock
New York
|
-$253K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$198K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$176K |
ADVM Hedge Fund Activity: Q1 2023 in Review
55 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2023, worth a combined $45M — up 36% from $33.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ADVM and 5 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 14 added.
The largest buyer was Commodore Capital, opening a new position worth an estimated $3.54M. The largest seller was Sonic GP LLC, cutting an estimated $1.8M.
- 55 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2023, down from 59 in Q4 2022.
- Funds reported $45M of Adverum Biotechnologies stock for Q1 2023, up 36% quarter-over-quarter.
- 5 funds opened new Adverum Biotechnologies positions in Q1 2023 and 9 closed out, a net change of -4 holders.
- The largest Adverum Biotechnologies buyer in Q1 2023 was Commodore Capital, an estimated $3.54M added.
- The largest Adverum Biotechnologies seller in Q1 2023 was Sonic GP LLC, an estimated $1.8M sold.
Based on aggregated 13F filings for Q1 2023.